BIBN 4096

Key Product Details

Product Description

BIBN 4096 is a potent and selective CGRP receptor antagonist (IC₅₀ values are 0.03 and 6.4 nM for human and rat CGRP receptors respectively). Displays high affinity for human CGRP receptors (K_i = 14.4 pM); exhibits no significant affinity for 75 other receptors. BIBN 4096 improves pain symptoms in a mouse migraine model.

Product Specifications for BIBN 4096

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for BIBN 4096

The following data is based on the product molecular weight 869.65.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

9 8 7 6 5 4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	2.30 mL	11.50 mL	23.00 mL
2.5 mM	0.46 mL	2.30 mL	4.60 mL
5 mM	0.23 mL	1.15 mL	2.30 mL
25 mM	0.05 mL	0.23 mL	0.46 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 66 publications citing the usage of this product.

• Rudolf Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1- piperidinyl J.Med.Chem. 2005 PMID: 16161996
• Prado TREK channel activation suppresses migraine pain phenotype. iScience 2021 PMID: 34458705
• Doods Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br.J.Pharmacol. 2000 PMID: 10711339

Product Documents for BIBN 4096